GT Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by GT Biopharma, Inc. (GTBP) on September 21, 2026, reporting events occurring on September 18, 2026. The Company, incorporated in Delaware and listed on The Nasdaq Stock Market, operates as a fully remote organization effective July 1, 2024, with no principal executive office.
Key Financial Metrics and Transaction Details
The filing details a private placement of Series M 10% Convertible Preferred Stock and associated warrants. Key transaction metrics include:
- Initial Offering (Sept 14, 2026): Up to 8,277.778 shares of Preferred Stock with an aggregate stated value of $8,277,778 for a purchase price of $7,450,000.
- Amended Offering (Sept 18, 2026): Increased to 8,611.111 shares of Preferred Stock with an aggregate stated value of $8,611,111.11 for a purchase price of $7,750,000.
- Greenshoe Option: Purchasers may elect to purchase additional Preferred Stock with an aggregate stated value of up to $34,675,615 for a purchase price of $31,208,054.
- Warrants: Includes Common Warrants equal to 100% of shares issuable upon conversion of Preferred Stock and Vesting Warrants related to the Greenshoe Right.
The filing does not provide specific revenue, profit, cash flow, margin, or existing debt figures. Liquidity impact is derived solely from the capital raised in this transaction.
Material Changes
The primary material change is the amendment of the Securities Purchase Agreement to increase the size of the offering and the admission of a new purchaser. Additionally, the Company filed a Certificate of Increase with the Delaware Secretary of State, raising the authorized shares of Series M Preferred Stock from 41,778 to 43,287 shares.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosures inherent in a private placement. The transaction was conducted pursuant to Rule 506(b) of Regulation D. The Company has agreed to file a registration statement for the public resale of the underlying common stock within 30 days of closing, with effectiveness targeted within 60 to 90 days depending on SEC review status.
Key Facts for Investor Verification
- Verify the final closing amount, including whether the $31.2 million Greenshoe option was exercised.
- Confirm the conversion price and terms of the Series M 10% Convertible Preferred Stock to assess potential dilution.
- Monitor the filing of the registration statement for the resale of common stock as required by the Registration Rights Agreement.
- Review the full text of the First Amendment to the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and liquidation preferences.